In addition, the hypoxia-activated prodrug tarloxotinib, concentrating high levels of active drug tarloxotinib-E (a potent and covalent pan-ErbB inhibitor) within the tumor microenvironment than normal tissue, has been reported of marked tumor response in HER2-activating mutations in NSCLC observed in the RAIN-701 study and in vitro models (Liu et al., 2020; Estrada-Bernal et al., 2021). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.